EMD SERONO

Pimicotinib demonstrated an increasing objective response rate from 54% at Week 25 to 76.2% at 14.3 months median follow-up in the global Phase 3 MANEUVER trial for tenosynovial giant cell tumor patients.

President Trump announced a deal with EMD Serono to reduce fertility medication costs, with Gonal-f available at an 84% discount for IVF patients.

New four-year data from CLARIFY-MS and MAGNIFY-MS studies demonstrate that 89.2% of relapsing multiple sclerosis patients treated with MAVENCLAD remained free from progression independent of relapse activity.

A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma.

Pimicotinib demonstrated a statistically significant 54.0% objective response rate versus 3.2% for placebo in the global Phase 3 MANEUVER trial for tenosynovial giant cell tumor.

PhaseV has raised $50 million in Series A funding led by Accel and Insight Partners, bringing its total funding to $65 million to expand its AI-driven clinical development platform.

Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.

Bionxt Solutions plans to initiate a clinical trial in the second half of 2025 to assess its sublingual cladribine formulation, BNT23001, for treating multiple sclerosis.

Only 39% of clinical trial sites achieve enrollment targets according to Tufts Center, highlighting critical recruitment challenges in drug development.